Plaque Psoriasis: Global Drug Forecast and Market Analysis to 2027

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Plaque Psoriasis: Executive Summary

2.1 Moderate Growth Is Expected for the plaque psoriasis Market from 2017–2027

2.2 R&D Strategies Target Moderate to Severe Patients

2.3 Opportunities Remain for Novel Oral and Topical Therapies

2.4 Pipeline Agents Provide Improved Treatment Options in the Crowded Market

2.5 What Do Physicians Think?

3 Introduction

3.1 Catalyst

3.2 Related Reports

3.3 Upcoming Related Reports

4 Disease Overview

4.1 Etiology and Pathophysiology

4.1.1 Etiology

4.1.2 Pathophysiology

4.2 Classification or Staging Systems

5 Epidemiology

5.1 Disease Background

5.2 Risk Factors and Comorbidities

5.3 Global and Historical Trends

5.4 Forecast Methodology

5.4.1 Sources

5.4.2 Forecast Assumptions and Methods

5.5 Epidemiological Forecast for Plaque Psoriasis (20172027)

5.5.1 One-Year Diagnosed Prevalent Cases of Plaque Psoriasis

5.5.2 Age-Specific One-Year Diagnosed Prevalent Cases of Plaque Psoriasis

5.5.3 Sex-Specific One-Year Diagnosed Prevalent Cases of Plaque Psoriasis

5.5.4 One-Year Diagnosed Prevalent Cases of Plaque Psoriasis by Severity

5.5.5 One-Year Diagnosed Prevalent Cases of Plaque Psoriasis with PsA

5.6 Discussion

5.6.1 Epidemiological Forecast Insight

5.6.2 Limitations of Analysis

5.6.3 Strengths of Analysis

6 Disease Management

6.1 Diagnosis and Treatment Overview

6.2 Leading Prescribed Drugs and Treatment Guidelines

6.3 US

6.4 5EU

6.5 Japan

7 Competitive Assessment

7.1 Overview

8 Unmet Needs and Opportunity Assessment

8.1 Overview

8.2 Lack of Oral Therapies

8.3 Lack of New Topical Therapies

8.4 Safe and Efficacious Drugs for Pregnant Women

8.5 Treatment Options for Mild Plaque psoriasis Patients

8.6 Education and Treatment of Psychological Factors Accompanying Plaque psoriasis

9 Pipeline Assessment

9.1 Overview

10 Current and Future Players

10.1 Overview

10.2 Trends in Corporate Strategy

10.3 Company Profiles

10.3.1 Johnson & Johnson

10.3.2 AbbVie

10.3.3 Amgen

10.3.4 Novartis

10.3.5 Pfizer

10.3.6 Eli Lilly

10.3.7 Merck

10.3.8 Leo Pharma

10.3.9 Celgene

10.3.10 Can-Fite Biopharma

10.3.11 UCB

10.3.12 Sun Pharma

11 Market Outlook

11.1 Global Markets

11.1.1 Forecast

11.1.2 Drivers and Barriers – Global Issues

11.2 US

11.2.1 Forecast

11.2.2 Key Events

11.2.3 Drivers and Barriers

11.3 5EU

11.3.1 Forecast

11.3.2 Key Events

11.3.3 Drivers and Barriers

11.4 Japan

11.4.1 Forecast

11.4.2 Key Events

11.4.3 Drivers and Barriers

12 Appendix

12.1 Bibliography

12.2 Abbreviations

12.3 Methodology

12.3.1 Forecasting Methodology

12.3.2 Diagnosed Patients

12.3.3 Percent Drug-Treated Patients

12.3.4 Drugs Included in Each Therapeutic Class

12.3.5 Launch and Patent Expiry Dates

12.3.6 General Pricing Assumptions

12.3.7 Individual Drug Assumptions

12.3.8 Generic Erosion

12.3.9 Pricing of Pipeline Agents

12.4 Primary Research – KOLs and Payers Interviewed for This Report

12.4.1 KOLs

12.4.2 Payers

12.5 Primary Research – Prescriber Survey

12.6 About the Authors

12.6.1 Analyst

12.6.2 Therapy Area Director

12.6.3 Epidemiologist

12.6.4 Managing Epidemiologist

12.6.5 Global Director of Therapy Analysis and Epidemiology

12.6.6 Global Head and EVP of Healthcare Operations and Strategy

12.7 About GlobalData

12.8 Contact Us

12.9 Disclaimer

Table 1: Plaque Psoriasis: Key Metrics in the 7MM

Table 2: Classification of Plaque Psoriasis

Table 3: Risk Factors and Comorbidities for Plaque Psoriasis

Table 4: Treatment Guidelines for Psoriasis

Table 5: Country Profile – US

Table 6: Country Profile – 5EU

Table 7: Country Profile – Japan

Table 8: Leading Treatments for Plaque psoriasis, 2018

Table 9: Johnson & Johnson’s Plaque psoriasis Portfolio Assessment, 2018

Table 10: AbbVie’s Plaque psoriasis Portfolio Assessment, 2018

Table 11: Amgen’s Plaque psoriasis Portfolio Assessment, 2018

Table 12: Novartis’ Plaque psoriasis Portfolio Assessment, 2018

Table 13: Pfizer’s Plaque psoriasis Portfolio Assessment, 2018

Table 14: Eli Lilly’s Plaque psoriasis Portfolio Assessment, 2018

Table 15: Merck’s Plaque psoriasis Portfolio Assessment, 2018

Table 16: Leo Pharma’s Plaque psoriasis Portfolio Assessment, 2018

Table 17: Celgene’s Plaque psoriasis Portfolio Assessment, 2018

Table 18: Can-Fite Biopharma’s Plaque psoriasis Portfolio Assessment, 2018

Table 19: UCB’s Plaque psoriasis Portfolio Assessment, 2018

Table 20: Sun Pharma’s Plaque psoriasis Portfolio Assessment, 2018

Table 21: Plaque psoriasis Market – Global Drivers and Barriers, 2017–2027

Table 22: Key Events Impacting Sales for Plaque psoriasis in the US, 2017–2027

Table 23: Plaque psoriasis Market – Drivers and Barriers in the US, 2017–2027

Table 24: Key Events Impacting Sales for Plaque psoriasis in the 5EU, 2017–2027

Table 25: Plaque psoriasis Market – Drivers and Barriers in the 5EU, 2017–2027

Table 26: Key Events Impacting Sales for Plaque psoriasis in Japan, 2017–2027

Table 27: Plaque psoriasis Market – Global Drivers and Barriers in Japan, 2017–2027

Table 28: Key Historical and Projected Launch Dates for Plaque psoriasis

Table 29: Key Historical and Projected Patent Expiry Dates for Plaque psoriasis

Table 30: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

Figure 1: Global Sales Forecast by Country for Plaque psoriasis in 2017 and 2027

Figure 2: Analysis of the Company Portfolio Gap in Plaque psoriasis During the Forecast Period

Figure 3: Competitive Assessment of the Late-Stage Pipeline Agents That GlobalData Expects to Be Launched for the Treatment of Plaque psoriasis During the Forecast Period

Figure 4: TNF Inhibitors and Interleukin Inhibitors in the Treatment of Plaque psoriasis

Figure 5: PDE4 Inhibitors in the Treatment of Plaque psoriasis

Figure 6: Age-Adjusted One-Year Diagnosed Prevalence of Plaque Psoriasis (%), Men and Women, Ages ≥18 Years, 2017

Figure 7: Sources Used and Not Used for One-Year Diagnosed Prevalent Cases of Plaque Psoriasis

Figure 8: Sources Used for One-Year Diagnosed Prevalent Cases of Plaque Psoriasis by Severity

Figure 9: Sources Used for One-Year Diagnosed Prevalent Cases of Plaque Psoriasis with PsA

Figure 10: One-Year Diagnosed Prevalent Cases of Plaque Psoriasis, 7MM, Men and Women, Ages ≥18 Years, 2017

Figure 11: Age-Specific One-Year Diagnosed Prevalent Cases of Plaque Psoriasis, 7MM, Men and Women, Ages ≥18 Years, 2017

Figure 12: Sex-Specific One-Year Diagnosed Prevalent Cases of Plaque Psoriasis, 7MM, Men and Women, Ages ≥18 Years, 2017

Figure 13: One-Year Diagnosed Prevalent Cases of Plaque Psoriasis by Severity, 7MM, Men and Women, Ages ≥18 Years, 2017

Figure 14: One-Year Diagnosed Prevalent Cases of Plaque Psoriasis with PsA, 7MM, Men and Women, Ages ≥18 Years, 2017

Figure 15: Diagnosis and Treatment of Plaque psoriasis

Figure 16: Unmet Needs and Opportunities in Plaque psoriasis

Figure 17: Overview of the Development Pipeline in Plaque psoriasis

Figure 18: Key Phase II/III Trials for the Promising Pipeline Agents that GlobalData Expects be Launched for Plaque psoriasis in the 7MM During the Forecast Period

Figure 19: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to be Launched for the Treatment of Plaque psoriasis During the Forecast Period

Figure 20: Analysis of the Company Portfolio Gap in Plaque psoriasis During the Forecast Period

Figure 21: Global (7MM) Sales Forecast by Country for Plaque psoriasis in 2017 and 2027

Figure 22: Sales Forecast by Class for Plaque psoriasis in the US in 2017 and 2027

Figure 23: Sales Forecast by Class for Plaque psoriasis in the 5EU in 2017 and 2027

Figure 24: Sales Forecast by Class for Plaque psoriasis in Japan in 2017 and 2027